Clarus Therapeutics, based in Northbrook, Illinois, is a biopharmaceutical company focused on the development and commercialization of androgen-based prescription drug products. Clarus' lead product is CLR-610, a proprietary oral testosterone product for the treatment of men with low testosterone levels. CLR-610 is an oral testosterone replacement product targeting a market that is currently dominated by gels. The gels suffer from considering safety issues related to transference and are inconvenient to patients. The company recently reported top-line results from their 90 day Phase 3 trial showing that 87% of men treated with CLR-610 achieved average serum testosterone levels in the normal range, supporting the study’s primary efficacy endpoint.

For more information visit: